IFU
ADMA icon

iSAM Funds (UK)’s ADMA Biologics ADMA Stock Holding History

iSAM Funds (UK)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,342
Closed -$34.3K – 308
2025
Q3 		$34.3K Buy
+2,342
New +$40.1K 0.01% 570

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

iSAM Funds (UK)'s ADMA Position: Q4 2025 in Review

iSAM Funds (UK) sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 2,342 shares — an estimated $34.3K sold.

iSAM Funds (UK) first reported a position in ADMA in Q3 2025 and held it in 1 quarter. The position peaked at $34.3K in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • iSAM Funds (UK) reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • iSAM Funds (UK) sold 2,342 ADMA Biologics shares in Q4 2025, an estimated $34.3K.
  • iSAM Funds (UK) first reported a position in ADMA Biologics in Q3 2025 and held it in 1 quarter.
  • iSAM Funds (UK)'s ADMA Biologics position peaked at $34.3K in Q3 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on iSAM Funds (UK)'s 13F filing for Q4 2025, filed 17 Feb 2026.